secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0000950170-23-009999
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals
--------------------------------------------------------------------------------

- FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.
- Restructuring substantially complete; $7.7M in charges incurred in 2022.
- AbbVie terminates CX-2029 collaboration; CytomX regains full rights to CD71 program.
- CX-904 Phase 1 dose escalation progressing; IND filings for CX-801 & CX-2051 expected 2H 2023.
- New collaborations: Moderna ($35M upfront) and Regeneron ($30M upfront) with up to $1.2B and $2B milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/0000950170-23-009999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023009999/ctmx-20230327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer